PDF Cover

Subdermal Contraceptive Implants Market

The market for Subdermal Contraceptive Implants was estimated at $1.1 billion in 2025; it is anticipated to increase to $1.5 billion by 2030, with projections indicating growth to around $2.0 billion by 2035.

Report ID:DS1806027
Author:Debadatta Patel - Senior Consultant
Published Date:
Datatree
Life Science
Other Healthcare
Subdermal Contraceptive Implants
Share
Report Summary
Market Data
Methodology
Table of Contents

Global Subdermal Contraceptive Implants Market Outlook

Revenue, 2025

$1.1B

Forecast, 2035

$2.0B

CAGR, 2026 - 2035

6.4%

The Subdermal Contraceptive Implants industry revenue is expected to be around $1.1 billion in 2026 and expected to showcase growth with 6.4% CAGR between 2026 and 2035. Subdermal contraceptive implants are a key component of contemporary long term reversible contraception. They have proven themselves to be very effective in the clinical trials which have been performed on them. Contraceptive implant sales are boosted by increased education on preventing unplanned pregnancies, governments paying for such procedures and services for family planning which are increasingly common especially in regions where women's reproductive health is prioritised. Almost 80% of those requiring the Subdermal Contraceptive Implant have their needs met by hospitals and clinics of gynecology. This shows how clinics providing specialist care are involved in Subdermal Contraceptive Implant insertion, follow up and advice. Industry revenue was led by the subdermal contraceptive implant in 2025 with sales of approximately $0.72 billion, the figure likely being influenced by the preference among medical professionals for established, single rod etonogestrel implants because they reduce inventory and training needs.

Subdermal contraceptive implants are inserted under the skin in the upper arm via a minor operation, they are thin and flexible rods. Once inserted, they release progestin which in turn prevents the occurrence of ovulation, it also thickens cervical mucus which prevents sperm from reaching the egg thereby preventing fertilization. Amongst their various benefits, the Long-Acting Reversible Contraception (LARC) contraception products include progestin only contraception, rapid return to fertility, multi year protection and maintenance free usage. These benefits make LARC devices suitable for those seeking contraceptive cover. Methods are used for routine birth control in teenagers and adults, family planning following childbirth and after miscarriage, and as part of public and private health programs. These are often given out through hospitals and clinics specialising in the health of women. The increasing popularity of Subdermal Contraceptive Implants is driven by the introduction of simpler applicators, by formulations of the hormones levonorgestrel and etonogestrel continuing to be refined, and through provider training programmes which help doctors in poorer countries, as well as the implementation of government policies favouring the use of long lasting contraceptive methods.

Subdermal Contraceptive Implants market outlook with forecast trends, drivers, opportunities, supply chain, and competition 2025-2035
Subdermal Contraceptive Implants Market Outlook

Market Key Insights

  • The Subdermal Contraceptive Implants market is projected to grow from $1.1 billion in 2025 to $2.0 billion in 2035. This represents a CAGR of 6.4%, reflecting rising demand across Long-term Birth Control, Hormonal Regulation, and Postpartum Contraception.

  • The market exhibits an oligopolistic structure with only 4 prominent players, with Organon & and Bayer AG commanding the largest shares.

  • The US and Germany are likely to dominate the subdermal contraceptive implants market in the coming years, with growth rates ranging from 4.2% to 6.1% between 2025 and 2030.

  • The highest growth is expected to occur in emerging markets such as Nigeria, Indonesia or Colombia, with a Compound Annual Growth Rate of between 7.4% and 8.8%.

  • Industry players are pushing the adoption of transitions like Increased Innovation and Variety for future years due to existing low growth of 6.4% ; but are also expected to invest $50 million by 2030.

  • The subcutaneous contraceptive implant market is due to grow by $0.9 billion over the period of 2025 to 2035 with manufacturers focusing their efforts on gynaecological clinics and commune health care centres.

  • As awareness about and educational standards rise and there are advances in healthcare technology, the market for subdermal contraceptive implants is anticipated to expand by 86% between 2025 and 2035.

subdermal contraceptive implants market size with pie charts of major and emerging country share, CAGR, trends for 2025 and 2032
Subdermal Contraceptive Implants - Country Share Analysis

Opportunities in the Subdermal Contraceptive Implants

The increasing prevalence of polycystic ovary syndrome and obesity in the United States makes it more difficult for oral contraceptives to be effective, resulting in patients opting for the implant. Using technology, it is possible to introduce online health care services which include automated follow up reminders, electronic consent and counseling over the phone. Electronic health records can also be linked with these outcomes to allow payers to track the results in value based contracts. Single rod devices which are MRI compatible and have improved hormones are likely to be the ones which will grow the fastest in this market, especially among privately insured 18 to 35 year old women who are digitally engaged.

Growth Opportunities in North America and Asia-Pacific

In North America, the implant is a premium kind of reversible contraception which lasts long and is placed under the skin. Those who give gynaecological care are the most important group using the product because of their high volume outpatient services for women and these also have a network of womens health. Companies in this field may create a niche by developing better, more user friendly hormonal implants which are more acceptable to patients. To grow, these companies should insert their products into healthcare programmes that are backed by insurance companies. The effectiveness of these products can be proved by using the data collected and this can be used to persuade insurance companies to include them in their coverage and treatment guidelines. In the global contraceptive implants industry, success is dependent on training of healthcare workers and clinical education as well as the brand power of major manufacturers of the product. Family planning services can be improved by use of workflow optimised insertion equipment. Among the factors driving the growth are the clinical guidelines that are in place for long acting reversible contraception, its insurance coverage, the drive to give women more control over their reproductive health and digital tools that make counselling and follow up easier.
The Subdermal Contraceptive Implant has its most significant market in the Asia Pacific for CHCC . This is because of the government run public health services in this region which cover all region's, be it urban or rural. Key region's of opportunity include the development of cost effective product lines, mid level provider friendly implant systems which permit task shifting, and participation in national tenders and the procurement channels of NGOs to increase the market presence of contraceptive implants. In the industry this market is in, factors that determine how companies compete include both large international businesses and local manufacturers which are rapidly expanding. The competition between the companies is influenced by the public health initiatives that local manufacturers tie their brand with, the companies local sourcing of their products and the bidding by the companies. In the region the main factors driving the market are rising demand for low cost family planning products, governments supporting health programmes concerning reproduction, the rapid growth of towns and cities and a rising awareness among young women for the use of long term reversible contraception.

Market Dynamics and Supply Chain

01

Driver: Increasing Demand for Long-Acting Reversible Contraception and Rising Women’s Health Awareness

The subdermal contraceptive implants market is also propelled by the growing preference for LARC and heightened awareness of women’s reproductive health. LARC methods like etonogestrel implants provide highly effective, low-maintenance birth control for up to three years, reducing daily adherence issues and improving contraceptive reliability. As healthcare providers emphasize patient-centered care, more women opt for implants over short-term methods such as pills or patches, especially in family planning and gynecology clinics where counseling services highlight convenience and efficacy. Simultaneously, rising awareness of reproductive choices, supported by public health initiatives and digital health education campaigns, empowers women to make informed decisions about contraception. Expansion of sexual health programs in both developed and emerging markets, along with efforts to destigmatize family planning, further also drives adoption. These trends encourage healthcare systems and payers to support implant accessibility and coverage, reinforcing long-term market growth for subdermal contraceptive technologies.
A key driver for subdermal contraceptive implants is also innovation in controlled hormone release and biocompatible materials. Improvements in polymer matrices and progestin delivery ensure consistent, predictable hormone dosing over extended durations, minimizing side effects and enhancing patient satisfaction. Enhanced implant designs also simplify insertion and removal procedures, lowering clinical barriers and increasing clinician adoption. This focus on advanced materials and delivery systems strengthens product differentiation and supports broader use across diverse patient populations.
02

Restraint: High Upfront Costs and Limited Insurance Coverage Restrict Implant Accessibility

One major restraint for subdermal contraceptive implants is the high upfront cost and variable insurance reimbursement, which can limit access, especially in low-income and uninsured populations. Although implants are cost-effective over time, initial placement costs-including device price, clinician fees, and follow-up visits-can deter patients and healthcare providers. In regions without strong public health funding or private coverage, demand declines, constraining market revenue and slowing broader adoption of long-acting contraception.
03

Opportunity: Rising adoption of single-rod subdermal contraceptive implants among urban working women in India’s metros and Government–donor partnerships scaling subdermal contraceptive implants within national public family-planning programs across Sub-Saharan Africa

Increasingly in Indian cities, there is a growing demand for a reliable, long lasting form of contraception. This is because many people are delaying marriage until their late twenties and are both working. The single rod implant is a medical device that is generating high revenue levels worldwide as of 2025. This form of birth control typically lasts three to five years and has minimal upkeep, making it suitable for career oriented women. The most under penetrated region of the market are corporate wellness clinics and private gynaecology. There is scope for increasing volumes in this region through payment plans which also offer guidance. Because they are easier to insert and have fewer side effects, single rod devices are expected to be more widely used than their multi rod counterparts. Additionally they result in faster patient recovery times.
In sub Saharan Africa, a substantial number of the population require access to contraception. This requirement exists despite severe constraints on health system budgets and staff. In comparison, subdermal implants offer protection for three years. They are consequently beneficial for public health clinics because they decrease the need for follow up visits. This is more than is true of the injectables or pill forms of contraception. By 2030, the market for single and multi rod devices is expected to be worth many billions of dollars. Governments and charitable donors are currently focusing their efforts on training midwives, task shifting and purchasing these devices in large quantities. The largest expansion is predicted in single rod implants distributed via mobile and community health workers as well as through outreach to rural districts.
04

Challenge: Cultural Stigma, Misconceptions, and Lack of Provider Training Reduce Adoption Rates

Another key restraint is sociocultural barriers, misinformation, and insufficient clinician training, which negatively influence demand for contraceptive implants. Misconceptions about hormonal side effects, fertility impacts, or procedural pain can discourage women from choosing implants. Additionally, in some healthcare settings clinicians lack confidence or training in insertion and removal techniques, leading to underutilization. These factors suppress product uptake, hinder market growth, and affect provider willingness to recommend implants despite proven efficacy.

Supply Chain Landscape

1

API Production

Merck & Co.Shanghai Dahua Pharmaceutical Co. Ltd
2

Implant Manufacturing

Organon & Co.Bayer AG
3

Packaging & Distribution

Merck & Co.Bayer AG
4

Clinical Utilization

Hospitals & ClinicsFamily Planning CentersReproductive Health Services
Subdermal Contraceptive Implants - Supply Chain

Use Cases of Subdermal Contraceptive Implants in Long-term Birth Control & Hormonal Regulation

Long-term Birth Control : Subdermal contraceptive implants such as etonogestrel implants (e.g., Nexplanon) are widely used for long-term birth control, providing reliable pregnancy prevention for up to three years with a single, minimally invasive placement. These hormone-releasing implants offer convenience, high efficacy, and rapid return to fertility after removal, making them popular among women seeking extended contraception. Leading providers like Organon (Nexplanon) and Merck maintain strong market positions through clinical evidence, global distribution, and practitioner training programs, enhancing uptake in family planning services.
Hormonal Regulation : In addition to preventing pregnancy, subdermal implants are used for hormonal regulation in women with menstrual disorders, dysmenorrhea, or endometriosis. By consistently delivering low doses of progestin, implants help stabilize hormonal fluctuations, reduce heavy bleeding, and alleviate pain. Devices like Implanon and Nexplanon are preferred in gynecology clinics due to predictable hormone release and minimal compliance concerns. Market leaders focus on safety profiles and patient education to support broader clinical acceptance.
Postpartum Contraception : Subdermal contraceptive implants are increasingly recommended for postpartum contraception, enabling new mothers to space pregnancies safely while breastfeeding. Because implants do not interfere with lactation and require no daily adherence, they are ideal for postpartum family planning. Healthcare systems and providers such as Organon and Bayer emphasize immediate post-delivery placement to enhance coverage and reduce unintended pregnancies. Strong manufacturer support in training and counseling strengthens provider confidence and patient satisfaction in maternal care settings.

Recent Developments

Recent developments in subdermal contraceptive implants reflect growing emphasis on long-acting reversible contraception, expanded family planning programs, and improvements in hormonal delivery technology that enhance efficacy and patient experience. Manufacturers are optimizing etonogestrel implant systems and training clinicians to support wider adoption. A key market trend is the integration of reproductive health equity initiatives, which increases access in developing regions and strengthens demand through public health campaigns, insurance coverage expansion, and enhanced clinician education across gynecology and maternal care settings.

August 2025 : Organon & Co. significantly expanded access to its single-rod subdermal contraceptive implant Implanon NXT by integrating it into India’s national family planning program across 16 states, increasing availability in public clinics and strengthening its position in the Asia-Pacific reproductive health market. 
March 2025 : Merck & Co., Inc. entered a strategic partnership with HRA Pharma to co-develop and commercialize a next-generation subdermal contraceptive implant, aimed at expanding global distribution and improving long-acting reversible contraception options. 

Impact of Industry Transitions on the Subdermal Contraceptive Implants Market

As a core segment of the Other Healthcare industry, the Subdermal Contraceptive Implants market develops in line with broader industry shifts. Over recent years, transitions such as Increased Innovation and Variety and Expansion of Accessibility have redefined priorities across the Other Healthcare sector, influencing how the Subdermal Contraceptive Implants market evolves in terms of demand, applications and competitive dynamics. These transitions highlight the structural changes shaping long-term growth opportunities.
01

Increased Innovation and Variety

With a growth rate of approximately 6.4% , the Subdermal Contraceptive Implants industry is to be characterised by increasing investment from major companies in the field to drive expansion and diversification. Investment of $43 million by 2030 is forecast. Investment is going into a new form of implantable birth control which improves performance, minimizes side effects and makes insertion and removal easier, thus subdermal contraceptive devices will now be considered a high end form of long lasting birth control. Through a combination of innovative materials, enhanced hormone pellets and less invasive delivery methods, pharmaceutical companies are looking to differentiate themselves from others, enhance patient compliance with medication and break into more lucrative markets. This development will speed up the entry of the contraceptive technology into the market in both emerging and established regions, thereby switching the market for subdermal contraceptive implants from one which experiences slow growth to a market that is characterised by innovation and rapid growth.
02

Expansion of Accessibility

The subdermal contraceptive implants market is undergoing a notable transition driven by improved healthcare access and equity in developing countries. Government-led family planning programs, support from international health organizations, and donor-funded initiatives have expanded the availability of implants in public healthcare systems. As a result, primary care clinics and maternal health centers increasingly offer long-acting reversible contraception as a standard option. This transition also impacts associated industries such as pharmaceutical manufacturing, medical training services, and public health supply chains, which are scaling production, distribution, and clinician education. Increased accessibility boosts procedure volumes, strengthens demand consistency, and supports long-term market expansion while contributing to broader maternal and reproductive health outcomes across underserved populations.